December 11th, 2017
jobs
homes

Menu
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NRX Pharmaceuticals, Inc. - Common Stock (NQ:NRXP)

3.443 +0.093 (+2.77%)
Streaming Delayed Price Updated: 10:26 AM EDT, Oct 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about NRX Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference
Via Investor Brand Network
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Present at Noble Capital Markets October 2025 Emerging Growth Virtual Equity Conference
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
$750 Million Market Projected to Reach $3.35 Billion in 2034; Mega Opportunity for Superior Preservative-Free Ketamine Drug Treating Suicidal Depression: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Re-files ANDA for Preservative-Free IV Ketamine KETAFREE(TM)
Via Investor Brand Network
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Re-Files Abbreviated New Drug Application (ANDA) for KETAFREE™, Preservative-Free IV Ketamine
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
FDA Approval of Suitability Petition on Superior Preservative-Free Ketamine Drug Supports $40 Price Target in H. C. Wainright Report on Leader in $3 Billion Suicidal Depression Market: NRXP
Via Get News
BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives FDA Approval of Suitability Petition for Preservative-Free Ketamine Product
Via Investor Brand Network
New to The Street's Prestigious Client NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx's Proposed Strength of Preservative-Free Ketamine
Via ACCESS Newswire
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx’s Proposed Strength of Preservative-Free Ketamine
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
$40 Price Target in New H. C. Wainright Analyst Report on Leader in $3 Billion Suicidal Depression Market with Superior NRX 100 Drug Therapy: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary HOPE Therapeutics Closes Acquisition of Dura Medical
Via Investor Brand Network
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Complete the Acquisition of Dura Medical; Initial Acquisition in Network of Interventional Psychiatry Clinics
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Join H.C. Wainwright’s 27th Annual Global Investment Conference; CEO Fireside Chat Set for Sept. 8, 2025, 4:30 to 5 p.m. ET
Via Investor Brand Network
NRx Pharmaceuticals (NASDAQ:NRXP) to Participate in a Fireside Chat at H.C. Wainwright's 27th Annual Global Investment Conference on Monday, September 8th
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
UPDATE -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller, Sponsored by Rockefeller Global Family Office
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Showcases HOPE Therapeutics at Global Passion Project Event
Via Investor Brand Network
NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Secures FDA Fast Track for IV Ketamine Formulation NRX-100 in Suicidal Depression
Via Investor Brand Network
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller and Rockefeller Capital
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
New to The Street T.V. Broadcasting on Bloomberg Saturday Aug 30th. The episode features TON Strategy Company (NASDAQ: TONX), Laser Photonics (NASDAQ: LASE), Sullivan & Cromwell Senior M&A Partner Frank Aquila, and Mercurity Fintech (NASDAQ: MFH)
Via ACCESS Newswire
BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announces Expanded Access Policy for NRX-100 Following FDA Fast Track Designation
Via Investor Brand Network
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Expanded Access Policy for NRX-100 (preservative-free ketamine)
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
NRx Pharmaceuticals' Approach To Treating Depression And Suicide Ideation Brings Modern Solution To Centuries-Old Problem
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
NRx Pharmaceuticals' Approach To Treating Depression And Suicide Ideation Brings Modern Solution To Centuries-Old Problem
Via TheNewswire.com
NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Seeks FDA Ban on Toxic Ketamine Preservative
Via Investor Brand Network
Advancements on Multiple Fronts in $3 Billion Suicidal Depression Market, Highlighted by FDA Fast Track Designation for Effective NRX 100 Drug Therapy: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Reports Q2 2025 Results, Highlights Progress Across Lead Programs and Strategic Investment
Via Investor Brand Network
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
From Novel Therapies To Treat Suicidal Bipolar Depression To Launching A Network Of Clinics, NRx Pharmaceuticals Is Getting Attention On Wall Street
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
From Novel Therapies To Treat Suicidal Bipolar Depression To Launching A Network Of Clinics, NRx Pharmaceuticals Is Getting Attention On Wall Street
Via TheNewswire.com
$3 Billion Suicidal Depression Market May Soon be Accessible via FDA Fast Track Designation for Effective NRX 100 Drug Therapy: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.